First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.

Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.

Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.

Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.

Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.

Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.

Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.

Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.

Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.

Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.